AGIO

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AGIO

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/11	20:00	GlobeNewswire Inc.	Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/09/05	20:00	GlobeNewswire Inc.	Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/14	05:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/14	05:12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/13	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/09	05:08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/07	06:50	GlobeNewswire Inc.	Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/01	22:49	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/01	20:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/01	19:31	GlobeNewswire Inc.	Agios Reports Business Highlights and Second Quarter 2024 Financial Results	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/08/01	19:30	GlobeNewswire Inc.	Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/07/18	20:00	GlobeNewswire Inc.	Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/18	06:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/18	06:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/18	06:20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/18	06:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/18	06:18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/18	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/15	21:45	GlobeNewswire Inc.	Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/08	05:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/06	22:00	GlobeNewswire Inc.	Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/06	08:50	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/06	05:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/06/03	19:30	GlobeNewswire Inc.	Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/05/31	05:05	GlobeNewswire Inc.	Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/05/28	20:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/05/28	20:00	GlobeNewswire Inc.	Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/05/14	23:00	GlobeNewswire Inc.	Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/05/06	20:00	GlobeNewswire Inc.	Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024	NASDAQ:AGIO	Agios Pharmaceuticals Inc
2024/05/03	20:00	GlobeNewswire Inc.	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024	NASDAQ:AGIO	Agios Pharmaceuticals Inc